
Kura Oncology (KURA) Stock Forecast & Price Target
Kura Oncology (KURA) Analyst Ratings
Bulls say
Kura Oncology is supported by a rapidly de-risking menin-inhibitor franchise, where KOMZIFTI generated $9.1MM in 2Q26 revenue, 115 new patient starts, and >250 total prescriptions, suggesting strong early commercialization and majority share in the NPM1-mutant AML launch segment. The company’s lead program also showed unusually strong clinical validation, with KOMET-007 delivering 96% CRc in NPM1-mutant AML, 94% 12-month OS, and durable MRD-negative responses, while a $519MM to $580.8MM cash position helps fund multiple registrational studies. Beyond hematology, darlifarnib is expanding the platform into solid tumors with encouraging early data in ccRCC and KRAS-mutant cancers, giving Kura optionality across two high-value oncology franchises.
Bears say
Kura Oncology is facing a fundamentally fragile outlook because its lead asset, ziftomenib, could prove less efficacious in AML than expected while its safety profile may offer little differentiation, prompting a reduced probability of success to 10%. The investment case is further weakened by the inherent risk of clinical trial failure, plus regulatory uncertainty around FDA and foreign approvals, any of which could delay or derail commercialization and pressure the share price. Even though the company is currently well-funded, it may still need additional equity financing to advance development, while intense competition and dependence on biomarker-driven patent strategies and sales execution add more downside risk.
This aggregate rating is based on analysts' research of Kura Oncology and is not a guaranteed prediction by Public.com or investment advice.
Kura Oncology (KURA) Analyst Forecast & Price Prediction
Start investing in Kura Oncology (KURA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Kura Oncology (KURA) Forecast
Kura Oncology (KURA) Analyst Forecast & Price Prediction
Start investing in Kura Oncology (KURA)
Order type
Buy in
Order amount
Est. shares
0 shares